You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 28, 2024

Claims for Patent: 9,724,310


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 9,724,310
Title:Transdermal estrogen device and delivery
Abstract: Described are transdermal drug delivery systems for the transdermal administration of estrogen, comprising a polymer matrix and estrogen. Methods of making and using such systems also are described.
Inventor(s): Mantelle; Juan (Miami, FL)
Assignee: Noven Pharmaceuticals, Inc. (Miami, FL)
Application Number:14/024,985
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 9,724,310
Patent Claims: 1. A monolithic transdermal drug delivery system for estradiol, consisting of (i) a backing layer, (ii) a single adhesive polymer matrix layer defining an active surface area and, optionally, (iii) a release liner, wherein the single adhesive polymer matrix layer comprises an adhesive polymer matrix comprising estradiol as the only drug, wherein the adhesive polymer matrix layer has a coat weight of greater than about 10 mg/cm.sup.2 and includes greater than 0.156 mg/cm.sup.2 estradiol, and the system achieves an estradiol flux of from about 0.0125 to about 0.05 mg/cm .sup.2 /day, based on the active surface area.

2. The transdermal drug delivery system of claim 1, wherein the adhesive polymer matrix comprises a polymer blend comprising an acrylic adhesive, a silicone adhesive, and soluble PVP.

3. The transdermal drug delivery system of claim 1, wherein the adhesive polymer matrix comprises about 2-25% by weight acrylic adhesive, about 45-70% by weight silicone adhesive, about 2-25% by weight soluble PVP, about 5-15% penetration enhancer, and about 0.1-10% by weight estradiol, all based on the total dry weight of the adhesive polymer matrix.

4. The transdermal drug delivery system of claim 3, wherein the penetration enhancer comprises oleyl alcohol.

5. The transdermal drug delivery system of claim 3, wherein the penetration enhancer comprises dipropylene glycol.

6. The transdermal drug delivery system of claim 3, wherein the penetration enhancer comprises oleyl alcohol and dipropylene glycol.

7. The transdermal drug delivery system of claim 3, wherein the acrylic adhesive and silicone adhesive are present in a ratio of from about 1:2 to about 1:6, based on the total weight of the acrylic and silicone adhesives.

8. The transdermal drug delivery system of claim 1, wherein the adhesive polymer matrix comprises an amount of estradiol effective to deliver a therapeutically effective amount of estradiol over a period of time selected from the group consisting of at least 1 day, at least 2 days, at least 3 days, at least 4 days, at least 5 days, at least 6 days and at least 7 days.

9. The transdermal drug delivery system of claim 1, wherein the adhesive polymer matrix comprises an amount of estradiol effective to deliver an amount of estradiol selected from the group consisting of about 0.025, 0.0375, 0.05, 0.075 and 0.1 mg/day.

10. The transdermal drug delivery system of claim 1, wherein the system achieves an estradiol flux of about 0.0125 mg/cm.sup.2/day, based on the active surface area.

11. The transdermal drug delivery system of claim 1, wherein the system achieves an estradiol flux of about 0.0133 mg/cm.sup.2/day, based on the active surface area.

12. The transdermal drug delivery system of claim 1, wherein the system achieves an estradiol flux of about 0.015 mg/cm.sup.2/day, based on the active surface area.

13. The transdermal drug delivery system of claim 1, wherein the system achieves an estradiol flux of about 0.0167 mg/cm.sup.2/day, based on the active surface area.

14. The transdermal drug delivery system of claim 1, wherein the system achieves an estradiol flux of about 0.0175 mg/cm.sup.2/day, based on the active surface area.

15. The transdermal drug delivery system of claim 1, wherein the adhesive polymer matrix comprises about 1.6% by weight estradiol, based on the total dry weight of the adhesive polymer matrix.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.